Another study has shown an inverse correlation between MAPK signalling and MYCN status in response to targeted therapy (MEK and CDK4/6 inhibitors) in preclinical models of NB, suggesting that therapy targeting the MAPK pathway could have improved efficacy when MYCN is not amplified83. The gene discussed is CDK4; the disease is neuroblastoma.